Anandhakrishnan Ananthi, Hussain Sufyan
Department of Diabetes, School of Cardiovascular, Metabolic Medicine and Sciences, King's College London, London, UK.
Department of Diabetes and Endocrinology, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Diabetes Obes Metab. 2024 Dec;26 Suppl 7(Suppl 7):27-46. doi: 10.1111/dom.15920. Epub 2024 Sep 18.
The development of automated insulin delivery (AID) systems, which connect continuous glucose monitoring (CGM) systems with algorithmic insulin delivery from an insulin pump (continuous subcutaneous insulin infusion, [CSII]), has led to improved glycaemia and quality of life benefits in those with insulin-treated diabetes. This review summarizes the benefits gained by the connectivity between insulin pumps and CGM devices. It details the technical requirements and advances that have enabled this, and highlights the clinical and user benefits of such systems. Clinical trials and real-world outcomes from the use of AID systems in people with type 1 diabetes (T1D) will be the focus of this article; outcomes in people with type 2 diabetes (T2D) and other diabetes subtypes will also be discussed. We also detail the limitations of current technological approaches for connectivity between insulin pumps and CGM devices. While recognizing the barriers, we discuss opportunities for the future.
自动胰岛素给药（AID）系统的发展，即将连续血糖监测（CGM）系统与胰岛素泵的算法胰岛素给药（持续皮下胰岛素输注，[CSII]）相连接，已使接受胰岛素治疗的糖尿病患者的血糖得到改善，并提高了生活质量。本综述总结了胰岛素泵与CGM设备连接所带来的益处。详细介绍了实现这一目标的技术要求和进展，并强调了此类系统的临床和用户益处。本文将重点关注1型糖尿病（T1D）患者使用AID系统的临床试验和实际应用结果；也将讨论2型糖尿病（T2D）和其他糖尿病亚型患者的结果。我们还详细阐述了当前胰岛素泵与CGM设备连接技术方法的局限性。在认识到这些障碍的同时，我们讨论了未来的机遇。
